Rubio-Lotvin B, Gonzales-Ansorena R
Acta Eur Fertil. 1978 Mar;9(1):1-6.
Experience with cyclic administration of 0.125 mg of norgestimate plus 0.035 mg of ethinyl estradiol indicates that this new combined oral contraceptive is clinically effective and well tolerated. There were no unintended pregnancies in 3,026 cycles of use among 161 women. Patient acceptability of a relatively high cycle incidence of spotting (16.7%) was remarkable; only five patients withdrew from the study because of this irregularity. Breakthrough bleeding was infrequent (0.9% of total cycles). No other side effects were reported and amenorrheic cycles were not observed. In particular there were no complaints of gastrointestinal disturbance. Weight remained unusually stable. Laboratory findings remained within normal limits over 6 months of drug use. However, serum cholesterol and serum glutamic pyruvic transaminase levels declined and protein bound iodine increased significantly from pre-treatment levels.
对0.125毫克诺孕酯加0.035毫克炔雌醇进行周期性给药的经验表明，这种新型复方口服避孕药在临床上有效且耐受性良好。161名女性在3026个使用周期中未出现意外怀孕情况。患者对相对较高的点滴出血周期发生率（16.7%）的接受度很高；只有5名患者因这种不规则情况退出了研究。突破性出血很少见（占总周期的0.9%）。未报告其他副作用，也未观察到闭经周期。特别是没有胃肠道不适的主诉。体重异常稳定。在用药6个月期间，实验室检查结果均在正常范围内。然而，血清胆固醇和血清谷丙转氨酶水平下降，蛋白结合碘较治疗前水平显著升高。
